Medtronic (MDT) Expected to Announce Earnings on Wednesday

Medtronic (NYSE:MDT) is anticipated to announce its Q4 2026 results before the market opens on Wednesday, June 3rd. Analysts expect the company to announce earnings of $1.56 per share and revenue of $9.6221 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Wednesday, June 3, 2026 at 7:45 AM ET.

Medtronic Stock Performance

Shares of NYSE MDT opened at $77.60 on Wednesday. The firm’s 50-day moving average price is $83.13 and its 200-day moving average price is $93.00. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The company has a market cap of $99.63 billion, a PE ratio of 21.62, a PEG ratio of 1.87 and a beta of 0.62. Medtronic has a 52-week low of $74.40 and a 52-week high of $106.33.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Hedge Funds Weigh In On Medtronic

Several large investors have recently added to or reduced their stakes in MDT. Acumen Wealth Advisors LLC purchased a new position in Medtronic during the fourth quarter valued at approximately $29,000. Imprint Wealth LLC purchased a new position in Medtronic during the third quarter valued at approximately $31,000. Chapman Financial Group LLC purchased a new position in Medtronic during the second quarter valued at approximately $37,000. JPL Wealth Management LLC purchased a new position in Medtronic during the third quarter valued at approximately $40,000. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Medtronic by 96.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 454 shares of the medical technology company’s stock valued at $44,000 after purchasing an additional 223 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on MDT shares. Argus dropped their price target on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Citigroup dropped their price target on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 price target on shares of Medtronic in a report on Tuesday, March 10th. Finally, Mizuho dropped their price target on shares of Medtronic from $125.00 to $120.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.45.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).